



**BENCH TO
BEDSIDE**
URO-ONCOLOGY
GU CANCER TRIAD



Register now!

SCIENTIFIC PROGRAMME COMMITTEE



Peter
BLACK
Canada



Peter
HAMMERER
Germany



Pilar
LAGUNA
Turkey



Rafael
SANCHEZ-SALAS
France

December 13–14, 2019 in Berlin, Germany

www.siu-urology.org



#B2BGUCancerTriad

Day 1
Friday, December 13, 2019



| TIME | SESSION TITLE | INVITED SPEAKERS |
|---|--|--|
| 0800 | Welcome and Introduction | Peter Black, Canada and Pilar Laguna, Turkey |
| Clinical Development of Immunotherapy for Bladder Cancer | | |
| 0815–0835 | Immunotherapy in Metastatic Urothelial Carcinoma | Petros Grivas, United States |
| Where to next? | | |
| 0835–0850 | Perioperative Immunotherapy for MIBC | Andrea Necchi, Italy |
| 0850–0905 | Combining Trimodal Therapy with Checkpoint Blockade | Wassim Kassouf, Canada |
| 0905–0920 | Immunotherapy and Evolving Therapies in NMIBC | Peter Black |
| 0920–0945 | Discussion / Q&A | Moderator: Peter Black Petros Grivas, United States Wassim Kassouf, Canada Andrea Necchi, Italy |
| 0945–1010 | Health Break | |
| Clinical Development of Immunotherapy for Kidney Cancer | | |
| 1010–1030 | Immunotherapy in Metastatic RCC | Christian Kollmannsberger, Canada |
| 1030–1115 | Multimodal Therapy of mRCC: Case-based Panel (to include discussion of cytoreductive Nx and SABR or surgery of mets) | Moderator: Michael Staehler, Germany Axel Bex, The Netherlands Dirk Böhmer, Germany Christian Kollmannsberger, Canada |
| 1115–1135 | Role of Perioperative IO and Targeted Therapy in High-risk RCC | Viktor Grünwald, Germany |
| Adverse Events/Toxicities | | |
| 1135–1220 | Case-based Discussions on Adverse Events / Toxicities Associated with Immunotherapy | Moderator: Kilian Gust, Austria Christian Kollmannsberger, Canada Pablo Maroto Rey, Spain Andrea Necchi, Italy Srikala Sridhar, Canada |
| 1220–1320 | Lunch Break | |
| Biomarkers of Response to Therapy | | |
| 1320–1405 | Developing Biomarkers for Clinical Utilization in Advanced Bladder Cancer: Panel Discussion | Moderator: Andrea Necchi, Italy Petros Grivas, United States Gopa Iyer, United States Tilman Todenhöfer, Germany |
| 1405–1435 | The Microbiome in Tumor Immunology | Lisa Derosa, France |
| 1435–1450 | Health Break | |
| The Pipeline | | |
| 1450–1510 | FGFR Inhibitors in Urothelial Carcinoma | Gopa Iyer, United States |
| 1510–1530 | Antibody Drug Conjugates in Urothelial Carcinoma | Srikala Sridhar, Canada |
| 1530–1550 | State of the Art: CAR-T-Cell Therapy | |
| 1550–1610 | Discussion | Moderators: Peter Black and Pilar Laguna Gopa Iyer, United States Srikala Sridhar, Canada |
| 1610–1630 | Concluding Remarks | Peter Black and Pilar Laguna |

Day 2
Saturday, December 14, 2019



| TIME | SESSION TITLE | INVITED SPEAKERS |
|---|--|---|
| Part I. Prostate Cancer I | | |
| 0800–0810 | Welcome Message | Peter Hammerer, Germany and Rafael Sanchez-Salas, France |
| 0810–0830 | Who and When: Germ-line DNA Testing in Prostate Cancer Patients | Thorsten Schlomm, Germany |
| Management of High Risk Non-metastatic Prostate Cancer | | |
| 0830–0845 | What is important for the surgeon? | Rafael Sanchez-Salas |
| 0845–0905 | What is important for the radiotherapist? | Alberto Bossi, France |
| 0905–0925 | Discussion (with Q&A) | Moderator: Peter Hammerer Alberto Bossi, France Rafael Sanchez-Salas Thorsten Schlomm, Germany |
| Managing Oligometastatic Prostate Cancer | | |
| 0925–0945 | Treatment of the Primary | Prasanna Sooriakumaran, United Kingdom |
| 0945–1005 | Definitive Treatment of the Mets | Dirk Böhmer, Germany |
| 1005–1025 | Systemic Therapy | Noel Clarke, United Kingdom |
| 1025–1110 | Case-based Panel Discussion (with Q&A) | Moderator: Rafael Sanchez-Salas Dirk Böhmer, Germany Karim Fizazi, France Peter Hammerer, Germany Noel Clarke, United Kingdom Prasanna Sooriakumaran, United Kingdom |
| 1110–1130 | Health Break | |
| Part II. Prostate Cancer II | | |
| 1130–1155 | Managing Biochemical Recurrence after Definitive Local Therapy: Case-based Panel Discussion (with Q&A) | Moderator: Peter Hammerer Alberto Bossi, France Axel Heidenreich, Germany Pablo Maroto Rey, Spain Derya Tilki, Germany Rafael Sanchez-Salas, France |
| 1155–1215 | Sequencing of Systemic Therapy for mCSPC & mCRPC | Karim Fizazi, France |
| 1215–1235 | Liquid Biopsy to Support Clinical Decision-making | Klaus Pantel, Germany |
| 1235–1255 | nmCRPC: Treatment Options in an Endangered Disease State | Antonio Alcaraz, Spain |
| 1255–1345 | Lunch Break | |
| mCRPC Systemic Therapy Pipeline | | |
| 1345–1405 | Immunotherapy | Pablo Maroto Rey, Spain |
| 1405–1425 | PARP Inhibitors | Noel Clarke, United Kingdom |
| 1425–1445 | PSMA-Theranostics | Frederik Giesel, Germany |
| 1445–1500 | Concluding Remarks | Peter Hammerer and Rafael Sanchez-Salas |



**BENCH TO
BEDSIDE**
URO-ONCOLOGY
GU CANCER TRIAD



Meeting Venue
Berlin Marriott Hotel
Inge-Beisheim-Platz 1
10785 Berlin, Germany

Registration Rates

Urologists
Medical Oncologists
Radiation Oncologists
Other Specialists

€150

Residents
Trainees
Fellows
Nurses

€65

TO REGISTER

www.siu-urology.org/academy/b2b-uro-oncology-the-gu-cancer-triad

This programme is made possible by unrestricted educational grants provided by Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd and Ferring Pharmaceuticals.